Scotland’s vaccination program drastically reduced COVID-19 hospital admissions, with the strongest real-world indication of the effectiveness of the AstraZeneca-Oxford vaccine suggesting that most of the world’s epidemics, according to the results of a study released on Monday Trusting to end.
The study examined the number of people hospitalized after receiving a single dose of the vaccine, incorporating both AstraZeneca and Pfizer-Bioentech vaccines. The UK has delayed delivering a second dose for three months for the first time, opting to offer partial protection of a single shot to more people.
But the study cautioned about how long a single dose would last a high safety level. The risk of hospitalization began a week later when people received their first shot, reaching a low point four to five weeks after vaccination. But then it appeared to rise again.
The scientists studying the study said that it is too early to know if more safety needs to be taken after one month about the safety given by the same dose.
Findings in Scotland suggest that earlier results from Israel show that vaccines provide significant protection from the virus. Israeli studies have focused on the Pfizer vaccine, but the Scottish study extended the AstraZeneca shot, which has been administered in Britain since early January. The AstraZeneca shot is the backbone of many countries’ inoculation plans: it is much cheaper to produce, and can be sent to and stored in a common refrigerator rather than an ultracold freezer used for other vaccines.
“These two are performing brilliantly,” Aziz Sheikh, a professor at the University of Edinburgh who was involved in the study, told a news conference on Monday.
Researchers in Scotland investigated hospital admission related to approximately 8,000 coronoviruses, and studied how the risk of hospitalization differed among those who did not receive the pill. In this period, researchers were studying how more than 1.1 million people were vaccinated in this period.
Researchers said that the number of people vaccinated was too low to care in hospitals to compare AstraZeneca and Pfizer vaccines or to give accurate figures of their effectiveness.
But 28 to 34 days after the first shot, the AstraZeneca vaccine reduced the risk of admission to the COVID-19 hospital by nearly 94 percent. Over the same time period, the Pfizer vaccine reduced the risk of hospitalization by approximately 85 percent. In both cases, those figures fit within a wide range of possible effects.
Because the Pfizer vaccine was authorized in the UK before the AstraZeneca shot, researchers had more data on the Pfizer vaccine, and found that protection against hospital admission was somewhat reduced in the long-term after the first shot.
“Peak safety is at four weeks, and then it starts dropping,” said Simon Clarke, a professor of cellular microbiology at the University of Reading who was not involved in the study.
The AstraZeneca vaccine has faced skepticism in parts of Europe, as many countries decided not to give it to older people, citing a lack of clinical trial data in that group. The Scottish study could not provide accurate figures on the effectiveness of that vaccine in older people. But the combined effect of AstraZeneca and Pfizer vaccine reduces hospital admission in more than 80 people. Many older people were given the AstraZeneca vaccine.